Table 5

Serum CEA and CA 15.3 levels in 53 patients undergoing chemotherapy for recurrent breast adenocarcinoma

No. of patientsSerum CEA levelsSerum CA 15.3 levels
No. positive (%)Mean ± SDMedian (range)aNo. positive (%)Mean ± SDMedian (range)a
Presurgeryb538 (15.1)3.5 ± 6.92.2 (0.6–44.2)21 (39.6)40.2 ± 40.826 (2.8–182.0)
Metastasesc5320 (37.7)16.4 ± 33.54.7 (0.3–156.9)d39 (73.6)162.4 ± 283.768.1 (13.1–1566.7)e
PDf3118 (58.1)22.5 ± 43.65.2 (0.1–214.0)27 (87.1)284.8 ± 478.8130.1 (14.6–2520.4)g
NC53 (60.0)13.1 ± 16.47.6 (2.4–42)4 (80.0)121.3 ± 71.3121.6 (27.0–212.4)
Responseh173 (17.7)4.2 ± 5.42.4 (0.1–22.3)g11 (64.7)52.0 ± 37.539.2 (21.4–157.4)g
  • a Mann-Whitney nonparametric U test between antigen levels at the time of diagnosis of metastatic disease and during therapy.

  • b Surgery of primary breast cancer.

  • c First diagnosis of metastasis.

  • d P < 0.002.

  • e P < 0.0001.

  • f PD, progression of disease; NC, no change.

  • g P < 0.05.

  • h Including partial or complete responses to chemotherapy.